GALECTIN THERAPEUTICS INC annual report, FY2021

Galectin Therapeutics Inc. — Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2021; filed March 31, 2022. The filing is an annual report, not a standalone fourth-quarter report. Galectin is a clinical-stage biopharmaceutical company with no commercial products or revenue. Its lead candidate is belapectin, a galectin-3 inhibitor being developed primarily for NASH cirrhosis and portal hypertension, with a secondary oncology program.

Business Context and Development Status

The primary program is NAVIGATE, an adaptive Phase 2b/3 global trial evaluating belapectin for prevention of esophageal varices in patients with compensated NASH cirrhosis and clinical signs of portal hypertension.
NAVIGATE had approximately 138 activated sites in 14 countries. Enrollment completion was targeted for June 30, 2022, but management stated that an additional quarter might be required, particularly because of slower European enrollment and continuing COVID-19 uncertainty.
A hepatic impairment study enrolled approximately 40 subjects and completed enrollment in February 2022. Results were not yet available in the filing.
The company was preparing an IND and planning a Phase 2 study of belapectin combined with a checkpoint inhibitor for recurrent or metastatic head and neck cancer.
Galectin Sciences LLC is developing small-molecule galectin-3 inhibitors that could potentially support oral delivery. Galectin’s ownership was 84.4% at December 31, 2021.

Financial Performance and Liquidity

Metric	2021	2020	Change
Revenue	$0	$0	No revenue generated
Research and development expense	$23.818 million	$17.976 million	Up 32%
General and administrative expense	$6.361 million	$5.468 million	Up 16%
Total operating expenses	$30.179 million	$23.444 million	Up $6.735 million
Net loss	$30.527 million	$23.465 million	Loss increased $7.062 million
Net loss attributable to common stockholders	$30.698 million	$23.602 million	Loss per share increased to $0.52 from $0.41
Net cash used in operating activities	$24.308 million	$20.601 million	Use increased $3.707 million
Cash and cash equivalents at year-end	$39.648 million	$27.142 million	Increased $12.506 million

Clinical-program spending was $20.830 million in 2021 versus $14.229 million in 2020, primarily reflecting NAVIGATE trial activities, clinical supplies, manufacturing, and related development work. General and administrative expense increased mainly because of higher stock-based compensation and insurance costs.

The company reported an accumulated deficit of $270.694 million at December 31, 2021. Management stated that existing unrestricted cash should fund currently planned operations through at least March 31, 2023, but approximately $45 million to $50 million of additional funding is expected to be required to reach the planned NAVIGATE interim analysis and support related activities. The filing states that failure to obtain additional capital could require the company to cease operations.

Debt, Financing, and Capital Structure

In 2021, the company received $30 million from three convertible notes issued to Chairman and shareholder Richard E. Uihlein: $10 million in April, $10 million in September, and $10 million in December.
The notes mature in 2025, bear stated interest at 2% annually, and are convertible at prices of $5.00, $8.64, and $5.43 per share, respectively, at the noteholder’s option.
Carrying value of related-party convertible notes and accrued interest, net of discounts, was $29.048 million at year-end. Related derivative liabilities totaled $1.130 million.
Additional 2021 financing included $3.864 million of net ATM proceeds and $2.950 million from warrant exercises. Common shares outstanding increased to 59.341 million from 57.077 million.
Outstanding warrants totaled 10.858 million at year-end, with a weighted-average exercise price of $4.37. Outstanding options totaled 4.896 million, with a weighted-average exercise price of $3.14.
The company has never paid cash dividends on common stock and does not expect to do so in the foreseeable future.

Material Changes Versus the Prior Comparable Period

Research and development expense increased 32%, driven by the NAVIGATE trial and supporting activities.
Total operating expenses increased 29%, while net loss increased approximately 30%.
Operating cash use increased 18%, from $20.601 million to $24.308 million.
Cash increased because $36.814 million of financing cash inflows, primarily related-party convertible debt, exceeded operating cash consumption.
Debt and derivative liabilities were newly significant balance-sheet items in 2021; year-end total liabilities increased to $39.211 million from $5.407 million.
Stockholders’ equity declined to $0.893 million from $22.470 million, primarily reflecting the year’s net loss.
Stock-based compensation increased to $2.076 million from $1.799 million.

Guidance, Outlook, Risks, and Unusual Items

Management expects continuing operating losses and no near-term revenue. Profitability depends on successful clinical development, regulatory approval, commercialization, reimbursement, and access to additional capital.
NAVIGATE enrollment and timelines remain subject to COVID-19 disruption, site activation, patient availability, regulatory approvals, and regional operating conditions. Management’s interim analysis timing was estimated for the first half of 2024.
The company relies on third-party contract research organizations, manufacturers, laboratories, and other vendors. It has no internal manufacturing facilities and generally purchases belapectin from suppliers on a purchase-order basis.
Earlier NASH studies provide supportive but mixed evidence: NASH-CX did not achieve a statistically significant primary endpoint in the total population, while certain analyses of patients without baseline esophageal varices showed favorable results. NASH-FX did not meet its primary endpoint.
All product candidates remain investigational. FDA or foreign regulatory approval is not assured, and promising earlier-stage data may not predict later-stage results.
The company’s related-party debt includes contingent-interest features requiring complex Level 3 derivative valuations. The filing identifies going concern, derivative valuation, and accrued clinical-trial expenses as critical audit matters.
Management reported effective disclosure controls and internal control over financial reporting. The independent auditor expressed an unqualified opinion on the consolidated financial statements but did not provide an audit opinion on internal control effectiveness because such an audit was not required.
No material pending legal proceedings were reported.

Investor Verification Checklist

Verify current NAVIGATE enrollment, interim-analysis timing, endpoint performance, dose selection, and any FDA interactions after the filing date.
Confirm current cash balances, quarterly cash burn, remaining trial commitments, and the timing and terms of required financing.
Review the three Uihlein convertible notes, including conversion mechanics, contingent-interest provisions, maturity dates, related-party governance, and potential dilution.
Reconcile outstanding warrants, options, deferred stock units, preferred-stock conversion rights, and other potential dilution to the current share count.
Assess whether NASH-CX and NAVIGATE patient-selection assumptions support the probability of success in the pivotal program.
Verify hepatic impairment study results and whether the company expands NAVIGATE eligibility beyond Child-Turcotte-Pugh Class A patients.
Monitor manufacturing capacity, supply continuity, third-party vendor dependence, and potential COVID-19 or other clinical-trial disruptions.
Review intellectual-property coverage, patent expiration dates, and the status of pending U.S. and foreign applications.